Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29061272 | 0.63 | — | — | |
| SCHEMBL29290128 | 0.62 | — | — | |
| SCHEMBL28523954 | 0.58 | — | — | |
| SCHEMBL18643305 | 0.53 | — | — | |
| SCHEMBL462712 | 0.52 | — | — | |
| Hydrochloric Acid SCHEMBL29889346 | 0.35 | — | — | |
| Hydrochloric Acid SCHEMBL6861827 | 0.29 | — | — | |
| Iodine SCHEMBL29421157 | 0.29 | — | — | |
| Iodine SCHEMBL31690775 | 0.29 | — | — | |
| Iodine SCHEMBL31690768 | 0.29 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137090-A1 | VIRAL ACTIVE AND/OR ANTI-MICROBIAL INKS AND COATINGS | GRAPHENE COMPOSITES LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| US-12550903-B2 | Viral active and/or anti-microbial inks and coatings | Graphene Composites Limited (GB) | 2026-02-17 | — | — | US | disclosed |
| EP-3400955-B1 | USE OF CRYPTONIN FOR TREATMENT OF CANCER | ISTANBUL UNIV REKTORLUGU (TR) | 2025-08-13 | — | — | EP | disclosed |
| US-20250195599-A1 | ANTI-DIABETIC STEROIDAL LACTONES OF WITHANIA COAGULANS FOR TREATMENT OF TYPE 2 DIABETES | UNIV KHALIFA SCIENCE & TECHNOLOGY (AE) | 2025-06-19 | — | — | US | disclosed |
| CN-119614363-A | Soil dehydrogenase detection equipment and detection method | 苏州梦犀生物医药科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-3749288-B1 | NANOPARTICLE-HYDROGEL COMPOSITE FOR NUCLEIC ACID MOLECULE DELIVERY | US HEALTH (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240252564-A1 | MIR-375- AND MIR-1-REGULATED COXSACKIEVIRUS B3 HAS NO PANCREAS AND HEART TOXICITY BUT STRONG ANTITUMOR EFFICIENCY IN COLORECTAL CARCINOMAS | UNIV BERLIN TECH (DE) | 2024-08-01 | — | — | US | disclosed |
| EP-3233102-B1 | USE OF AN ANTIMICROBIAL PEPTIDE TO INDUCE CELL DEATH IN BREAST CANCER | BOLKENT SEHNAZ (TR) | 2024-03-06 | — | — | EP | disclosed |
| US-11904057-B2 | Nanoparticle-hydrogel composite for nucleic acid molecule delivery | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230321175-A1 | ANTI-DIABETIC STEROIDAL LACTONES OF WITHANIA COAGULANS FOR TREATMENT OF TYPE 2 DIABETES | Khalifa University of Science and Technology (AE) | 2023-10-12 | — | — | US | disclosed |
| US-20160106792-A1 | TREATMENT OF CANCER | CARMEL HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2016-04-21 | — | — | US | disclosed |
| EP-3007712-A1 | TREATMENT OF CANCER | Carmel-Haifa University Economic Corporation Ltd (IL) | 2016-04-20 | — | — | EP | disclosed |
| WO-2015112841-A1 | EXTRACT OF ARTEMISIA ANNUA | AL-TAWASHI AZZA (QA) | 2015-07-30 | — | — | WO | disclosed |
| WO-2014199379-A1 | TREATMENT OF CANCER | CARMEL HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014165818-A2 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PROSTATE CANCER | T CELL THERAPEUTICS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140187505-A1 | Cardiac Glycosides to Treat Cystic Fibrosis and Other IL-8 Dependent Disorders | POLLARD BETTE (US) | 2014-07-03 | — | — | US | disclosed |
| US-8636711-B2 | Stabilized glucagon solutions and uses therefor | LEGACY EMANUEL HOSPITAL & HEALTH CENTER (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120071817-A1 | STABILIZED GLUCAGON SOLUTIONS AND USES THEREFOR | LEGACY EMANUEL HOSPITAL & HEALTH CENTER (US) | 2012-03-22 | — | — | US | disclosed |
| WO-1999023215-A9 | MATERIALS AND METHODS FOR PREVENTING CELLULAR INJURY IN HUMANS AND ANIMALS | UNIV FLORIDA (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999023215-A2 | MATERIALS AND METHODS FOR PREVENTING CELLULAR INJURY IN HUMANS AND ANIMALS | UNIVERSITY OF FLORIDA (US) | 1999-05-14 | — | — | WO | disclosed |